脓毒血症和脓毒血性休克的抗生素治疗(重庆会议)资料.ppt

* * Slide 10 * * As with the polymyxins, clinical experience with tigecycline for MDR gram-negative organisms remains limited mostly to case reports and case series. However, Vasilev et al conducted an open-label, noncomparative, multicenter study of tigecycline for the treatment of patients with serious infections caused by MDR gram-negative organisms. After a loading dose of 100 mg, tigecycline was dosed at 50 mg every 12 hours for 7-28 days. A patient was considered to have an MDR organism if any of the following were true: 1) it was a documented ESBL producer; 2) the patient had failed cli